Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 320-326

  Vergote, Ignace B ^a   Jimeno, Antonio ^c   Joly, Florence ^d   Katsaros, Dionyssios ^j   Coens, Corneel ^b   Despierre, Evelyn ^a   Marth, Christian ^m   Hall, Marcia ^o   Steer, Christopher B ^r   Colombo, Nicoletta ^l   Lesoin, Anne ^e   Casado, Antonio ^t   Reinthaller, Alexander ⁿ   Green, John ^p   Buck, Martin ^s   Ray Coquard, Isabelle ^f   Ferrero, Annamaria ^k   Favier, Laure ^g   Reed, Nick Simon ^q   Curé, Hervé ^h   Pujade Lauraine, Eric ⁱ   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f CENTRE LÉON BÉRARD   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h INSTITUT JEAN GODINOT   (France)

ⁱ HÔTEL DIEU   (France)

^j UNIVERSITY OF TURIN   (Italy)

^k MAURIZIANO HOSPITAL   (Italy)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o MOUNT VERNON CANCER CENTRE   (United Kingdom)

^p UNIVERSITY OF LIVERPOOL   (United Kingdom)

^q GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^r Border Medical Oncology Australia   (Australia)

^s DEPARTMENT OF HEALTH   (Australia)

^t HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GAMMA GLUTAMYLTRANSFERASE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PLATINUM DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL OBSERVATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOSS OF APPETITE; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; CANCER STAGING; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EUROPE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; SIGNAL TRANSDUCTION; UTERINE TUBE TUMOR; VERY ELDERLY; WATCHFUL WAITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; EUROPE; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PLATINUM COMPOUNDS; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; WATCHFUL WAITING;

EID: 84897020192     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.5669     Document Type: Article

References (29)

1. Ferlay J, Parkin DM, Steliarova-Foucher E, et al: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781, 1996
2. Vergote I, Tropé CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
3. Trimbos JB, Vergote I, Bolis G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for the Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 95:113-125, 2003 (Pubitemid 36193260)
4. Skirnisdóttir I, Sorbe B, Seidal T: The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 11:119-129, 2001 (Pubitemid 32381660)
5. Fischer-Colbrie J, Witt A, Heinzl H, et al: EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Anticancer Res 17:613-619, 1997 (Pubitemid 27105536)
6. Bast RC Jr, Pusztai L, Kerns BJ, et al: Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p17EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17:313-321, 1998 (Pubitemid 28462613)
7. Harlozińska A, Bar JK, Sobańska E, et al: Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumour Biol 19:364-373, 1998 (Pubitemid 28384462)
8. Ilekis JV, Connor JP, Prins GS, et al: Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66:250-254, 1997 (Pubitemid 27335412)
9. Srkalovic G, Schally AV, Wittliff JL, et al: Presence and characteristics of receptors for [D-Trp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12:489-498, 1998 (Pubitemid 28097966)
10. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087-4091, 1990 (Pubitemid 20225635)
11. Slamon DJ, Godolphin W, Jones LA, et al: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989 (Pubitemid 19147683)
12. Heuckmann JM, Rauh D, Thomas RK: Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol 30:3417-3420, 2012
13. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance therapy in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
14. Hirte H, Oza A, Swenerton K, et al: A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol Oncol 118:308-312, 2010
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Vergote I, Rustin GJ, Eisenhauer EA, et al: Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst 92:1534-1535, 2000
17. Marth C, Egle D, Auer D, et al: Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab. Gynecol Oncol 105:716-721, 2007 (Pubitemid 46734201)
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998 (Pubitemid 28041591)
20. Fairclough DL: Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL, Chapman & Hall/CRC Press, 2002, pp 118-125
21. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205. J Clin Oncol 28:3605-3610, 2010
22. Schilder RJ, Sill MW, Chen X, et al: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin Cancer Res 11:5539-5548, 2005 (Pubitemid 41060831)
23. Gordon AN, Finkler N, Edwards RP, et al: Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 15:785-792, 2005 (Pubitemid 41783082)
24. Hirsch FR, Varella-Garcia M, Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28:S32-S37, 2009
25. Petrelli F, Borgonovo K, Cabiddu M, et al: Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13 randomized trials. Clin Lung Cancer 13:107-114, 2012
26. Weberpals JI, Koti M, Squire JA: Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet 204:525-535, 2011
27. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 37:S9-S15, 2001 (Pubitemid 32938124)
28. Lee SM, Khan I, Upadhyay S, et al: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): A double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13:1161-1170, 2012
29. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011